[Inhibitory effect of kukoamine B on lung inflammatory responses in mice with sepsis]

Jinli Zhang1, Weiting Qin, Wanghui Lyu

  • 1Department of Burns and Plastic Surgery, Affiliated Hospital, Jiangsu University, Zhenjiang 212001, Jiangsu, China. Corresponding author: Sun Bingwei,

Abstract

Insights

Kukoamine B (KB) effectively neutralizes lipopolysaccharide (LPS) to reduce lung inflammation in septic mice. This study shows KB inhibits inflammatory mediators and protects lung function, offering a potential therapeutic strategy.

Area of Science:

  • Pharmacology and Toxicology
  • Immunology
  • Sepsis Research

Context:

  • Sepsis is a life-threatening condition characterized by a dysregulated host response to infection, often leading to organ damage, particularly in the lungs.
  • Lipopolysaccharide (LPS) is a major component of Gram-negative bacteria that triggers potent inflammatory responses, contributing to sepsis-induced lung injury.
  • Kukoamine B (KB) is a compound being investigated for its potential anti-inflammatory properties.

Purpose:

  • To evaluate the inhibitory effects of Kukoamine B (KB) on lung inflammatory responses in a mouse model of sepsis.
  • To elucidate the molecular mechanisms underlying KB's protective effects against sepsis-induced lung inflammation.

Summary:

  • Sepsis was induced in mice using lipopolysaccharide (LPS). Kukoamine B (KB) was administered to assess its impact on inflammatory markers and lung tissue.
  • KB treatment significantly reduced LPS levels, myeloperoxidase activity, and the expression of nuclear factor-kappa B (NF-κB) and inducible nitric oxide synthase (iNOS) in lung tissue.
  • KB also decreased the levels of pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β) in plasma, bronchoalveolar lavage fluid, and lung homogenates. Histological analysis revealed attenuated leukocyte infiltration and reduced intercellular adhesion molecule-1 (ICAM-1) expression in the lungs of KB-treated mice.

Impact:

  • Kukoamine B demonstrates significant potential in mitigating LPS-induced lung inflammation and protecting lung function in a sepsis model.
  • The findings suggest KB acts by neutralizing LPS, inhibiting inflammatory mediator release, and reducing NF-κB pathway activation.
  • KB represents a promising therapeutic candidate for managing sepsis-induced pulmonary complications.

Related Concept Videos